Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers

Recommendations for the management of cutaneous adverse effects of inhibitors of the epidermal growth factor receptor (EGFR) are urgently needed. In this context an expert panel of German dermatologists recently proposed a 3‐step management concept based on personal experience and a current literature consensus. While steps 1 and 2 addressed general and preventive measures, as well as the therapy that can be performed by the primary treating physician, here we address the management of challenging cases (step 3) that do not respond well to basic measures and should be referred to an experienced dermatologist.

[1]  J. Bernier,et al.  Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Enk,et al.  Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[3]  A. Hauschild,et al.  Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  B. Homey,et al.  Density of Demodex folliculorum in Patients Receiving Epidermal Growth Factor Receptor Inhibitors , 2011, Dermatology.

[5]  K. Kudo,et al.  Toxicity manifesting as cosmetic hair alterations during erlotinib treatment , 2011, Acta oncologica.

[6]  M. Steinhoff,et al.  Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. , 2010, Journal of the American Academy of Dermatology.

[7]  M. Lacouture,et al.  Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. , 2010, Journal of the National Cancer Institute.

[8]  A. Wollenberg,et al.  Microbiological analysis of epidermal growth factor receptor inhibitor therapy‐associated paronychia , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[10]  Lynne Wagner,et al.  A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group , 2010, Supportive Care in Cancer.

[11]  B. Homey,et al.  The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Matuschek,et al.  Development and Management of Severe Cutaneous Side Effects in Head-and-Neck Cancer Patients during Concurrent Radiotherapy and Cetuximab , 2008, Strahlentherapie und Onkologie.

[13]  A. Rademaker,et al.  Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results , 2007, Oncology.

[14]  A. del Palacio,et al.  Erlotinib associated with rosacea‐like folliculitis and Malassezia sympodialis , 2006, The British journal of dermatology.

[15]  R. Gutzmer,et al.  Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy , 2005, The British journal of dermatology.

[16]  E. Van Cutsem,et al.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Kris,et al.  Practical management of patients with non-small-cell lung cancer treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Halpern,et al.  Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.

[19]  F. Forton,et al.  Density of Demodex folliculorum in rosacea: a case‐control study using standardized skin‐surface biopsy , 1993, The British journal of dermatology.